{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"1.5","value":"1.12"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"3.9","value":"1.92"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"1.2","value":"0.63"},{"groupId":"OG003","lowerLimit":"0.5","upperLimit":"1.0","value":"0.84"},{"groupId":"OG004","lowerLimit":"1.8","upperLimit":"7.1","value":"3.50"},{"groupId":"OG005","lowerLimit":"1.1","upperLimit":"5.4","value":"2.12"},{"groupId":"OG006","lowerLimit":"1.6","upperLimit":"11.7","value":"4.25"},{"groupId":"OG007","lowerLimit":"0.5","upperLimit":"4.3","value":"2.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"14"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1"},{"categories":[{"measurements":[{"groupId":"OG004","lowerLimit":"0.7","upperLimit":"24.3","value":"3.72"},{"groupId":"OG006","lowerLimit":"1.7","upperLimit":"9.0","value":"3.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"5.4","value":"3.23"},{"groupId":"OG004","lowerLimit":"3.0","upperLimit":"8.6","value":"4.39"},{"groupId":"OG005","lowerLimit":"0.6","upperLimit":"8.6","value":"1.32"},{"groupId":"OG006","lowerLimit":"1.4","upperLimit":"6.2","value":"3.62"},{"groupId":"OG007","lowerLimit":"0.6","upperLimit":"4.3","value":"2.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"5"}],"units":"Participants"}],"title":"WEEK 4 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"1.7","upperLimit":"1.7","value":"NA"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"6.4","value":"3.90"},{"groupId":"OG002","lowerLimit":"0.6","upperLimit":"2.8","value":"1.24"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"0.7","upperLimit":"1.9","value":"NA"},{"groupId":"OG004","lowerLimit":"4.0","upperLimit":"8.1","value":"5.85"},{"groupId":"OG005","lowerLimit":"0.1","upperLimit":"3.7","value":"2.72"},{"groupId":"OG006","lowerLimit":"5.7","upperLimit":"13.9","value":"10.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 7 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG002","lowerLimit":"0.6","upperLimit":"0.7","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG004","lowerLimit":"6.6","upperLimit":"6.6","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"4.9","upperLimit":"4.9","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG007","lowerLimit":"4.9","upperLimit":"4.9","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"WEEK 10 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG000","lowerLimit":"3.2","upperLimit":"3.2","value":"NA"},{"groupId":"OG002","lowerLimit":"0.7","upperLimit":"2.1","value":"1.40"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG003","lowerLimit":"2.0","upperLimit":"3.4","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG005","lowerLimit":"6.3","upperLimit":"6.3","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"10.3","upperLimit":"10.3","value":"NA"},{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG007","lowerLimit":"1.5","upperLimit":"5.7","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"title":"WEEK 13 DAY 1"},{"categories":[{"measurements":[{"comment":"As pre-specified in the SAP, median is not reported if the number of participants analyzed is less than 3.","groupId":"OG006","lowerLimit":"1.7","upperLimit":"1.7","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"WEEK 13 DAY 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"14"}],"units":"Participants"}],"description":"Blood samples were collected at indicated timepoints for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of every alternate 21-day cycle (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib (Bor) was administered as 1.3 milligrams per square meters (mg/m\\^2) subcutaneously (SC) /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone (Dex) PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG000","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 1.9 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG001","title":"Main Study Phase: Belantamab Mafodotin 1.9 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on cycle 1 day 1 (C1D1) followed by 1.9 mg/kg step-down dose on Day 1 of every alternate 21-day cycles C3 onwards (C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG002","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg Step-Down STRETCH+ Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every alternate 21-day cycles (C1, C3, C5, C7, and so on) as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG003","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg STRETCH + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 2.5mg/kg dose as a 1.25 mg/kg on Day 1 and 1.25 mg/kg dose on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG004","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 2.5 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG005","title":"Main Study Phase: Belantamab Mafodotin 2.5 mg/kg SINGLE + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as two equal divided doses of a total 3.4 mg/kg dose as a 1.7 mg/kg dose on Day 1 and 1.7 mg/kg on Day 8 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG006","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SPLIT + Bor/Dex"},{"description":"Participants with RRMM received belantamab mafodotin as SINGLE full dose of 3.4 mg/kg on Day 1 of every 21-day cycle as a 30-60 minute infusion. Along with belantamab mafodotin, Bortezomib was administered as 1.3 mg/m\\^2 SC /IV on Days 1, 4, 8, and 11 with 20 mg Dexamethasone PO/IV on Days 1, 2, 4, 5, 8, 9, 11, and 12 of every 21-day cycle up to 8 cycles.","id":"OG007","title":"Main Study Phase: Belantamab Mafodotin 3.4 mg/kg SINGLE + Bor/Dex"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic (PK) population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose, Post-Dose 0, 2 and 24 Hour on Cycle 1 Day 1 and Cycle 1 Day 8; Pre-Dose and Post-Dose on Week 4 Day 1, Week 7 Day 1, Week 10 Day 1, Week 13 Day 1, Week 13 Day 8","title":"Ctrough for Belantamab Mafodotin ADC, Treatment B","type":"SECONDARY","unitOfMeasure":"ug/mL"}